ArticleFrontiers in cellular and infection microbiology2023
Resistance against two lytic phage variants attenuates virulence and antibiotic resistance in
Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Giving Antibiotics a Second Chance: Evolutionary Trade-Offs and Phage-Driven Restoration of Antibiotic Susceptibility.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Review
- Isolation of a Novel Lytic Pseudomonas aeruginosa Phage Henu5 and Fitness Costs of Phage-Driven Resistance.Microbial biotechnology · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Article
- Immuno-phage synergy driven by fitness costs: turning bacterial phage resistance into therapeutic gain through evolutionary traps.Frontiers in immunology · 2026Review
- A lytic bacteriophage vB_KpnP-6K2 inhibits ST11-KL64Frontiers in cellular and infection microbiology · 2026Article
- Phage isolation and functional characterization reveal strong antibiofilm activity againstFrontiers in cellular and infection microbiology · 2026Article
- Effect of PGPB-enriched organic fertilizer ORGAONEnvironmental microbiome · 2025Article
- Phage Therapy as a Novel Alternative to Antibiotics Through Adaptive Evolution and Fitness Trade-Offs.Antibiotics (Basel, Switzerland) · 2025Review
- A case report of bacteriophage therapy for the treatment of lung infection due to carbapenem-resistant Pseudomonas aeruginosa.Scientific reports · 2025Article
- Reviving the past for a healthier future: ancient molecules and remedies as a solution to the antibiotic crisis.Future microbiology · 2025Review
- Study of the probability of resistance to phage infection in a collection of clinical isolates ofMicrobiology spectrum · 2025Article
- Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens.Therapeutic delivery · 2025Review
- Lytic bacteriophages as alternative to overcoming antibiotic-resistant biofilms formed by clinically significant bacteria.Therapeutic advances in infectious diseaseReview
Corrections and comments
- Erratum issued
Authors and funding
25 authors at 10 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bacteriophage therapy is becoming part of mainstream Western medicine since antibiotics of clinical use tend to fail. It involves applying lytic bacteriophages that self-replicate and induce cell lysis, thus killing their hosts. Nevertheless, bacterial killing promotes the selection of resistant clones which sometimes may exhibit a decrease in bacterial virulence or antibiotic resistance. Methods: In this work, we studied the Results: Phage φDCL-PA6α differs from the original by only two amino acids: one in the baseplate wedge subunit and another in the tail fiber protein. According to genomic data and cross-resistance experiments, these changes may promote the change of the phage receptor from the O-antigen to the core lipopolysaccharide. Interestingly, the host range of the two phages differs as determined against the Conclusions: We show as well that phage resistance impacts virulence factor production. Specifically, phage resistance led to decreased biofilm formation, swarming, and type III secretion; therefore, the virulence towards Galleria mellonella was dramatically attenuated. Furthermore, antibiotic resistance decreased for one clinical strain. Our study highlights important potential advantages of phage therapy's evolutionary impact that may be exploited to generate robust therapy schemes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.